Frankincense (AKBA) — The 5-LOX Inhibitor

AKBA (3-O-acetyl-11-keto-beta-boswellic acid) is the most potent naturally occurring inhibitor of 5-lipoxygenase (5-LOX), an enzyme responsible for the synthesis of pro-inflammatory leukotrienes. By directly binding to and inhibiting 5-LOX, AKBA suppresses the leukotriene inflammatory cascade, which is implicated in chronic low-grade inflammation (inflammaging). Additionally, AKBA has been shown to inhibit the activation of NF-κB, a master regulator of inflammatory gene expression, and reduce the production of pro-inflammatory cytokines such as TNF-α and IL-1β. It also exhibits antioxidant properties by mitigating reactive oxygen species (ROS) production.

Multiple double-blind, placebo-controlled human trials have demonstrated the efficacy of AKBA-enriched Boswellia extracts in reducing pain and improving physical function in patients with osteoarthritis. Studies such as Sengupta et al. (2008) and Vishal et al. (2011) show significant improvements in joint comfort and mobility, sometimes within 7 days of supplementation. No published human longevity trials. Animal/in-vitro evidence only for systemic anti-aging effects.

100–250 mg/day of AKBA-enriched Boswellia serrata extract (e.g., 5-Loxin or Aflapin, standardized to 20-30% AKBA) is the most studied range in humans for joint health. Best taken with food, particularly a fat source, to improve its naturally poor bioavailability. Some formulations use liposomal or phytosome delivery systems to enhance absorption.

Generally well-tolerated in clinical trials at standard doses. Mild adverse effects may include gastrointestinal discomfort, acid reflux, or nausea. Due to its anti-inflammatory and potential antiplatelet effects, caution is advised when combining with NSAIDs or blood-thinning medications. Safety in pregnancy and lactation is unestablished.

Key Papers